These findings have clinical relevance because they provide a rationale to test COX-2 inhibition as a potential treatment to prevent PTC progression and enhance the antitumor activity of other cancer therapies to treat patients with aggressive PTC and BRAF mutations. This evidence concerns the gene PTGS2 and cancer.